Q2 2026 Biofrontera Inc Earnings Call Transcript

Aug 13, 2026 / 02:00 PM GMT

Release Date Price: $0.063

Transcript 10-Q8-K

Key Points

Positve

Biofrontera Inc (BFRI) reported a strong quarter with significant revenue growth, driven by increased sales of its lead product Ameluz.
The company successfully expanded its commercial team and increased market penetration in the U.S., leading to higher prescription volumes.
Biofrontera Inc (BFRI) achieved a notable improvement in gross margin, reflecting better cost management and operational efficiencies.
The company maintained a solid cash position, providing sufficient runway to fund ongoing operations and strategic initiatives.
Management highlighted positive clinical data updates for pipeline candidates, which could diversify future revenue streams.

Negative

Biofrontera Inc (BFRI) continues to face intense competition in the dermatology market, which may pressure pricing and market share.
The company's operating expenses increased significantly due to higher sales and marketing investments, impacting profitability.
Biofrontera Inc (BFRI) remains dependent on a limited product portfolio, exposing it to concentration risk if Ameluz sales underperform.
Regulatory and reimbursement challenges persist, potentially hindering broader adoption of its products in key markets.
The company's net loss widened compared to the prior year, indicating ongoing challenges in achieving sustainable profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BFRI.OQ - Biofrontera Inc
Q2 2026 Biofrontera Inc Earnings Call
Aug 13, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------

--------------------------------------------------------------------------
Definitions
--------------------------------------------------------------------------
PRELIMINARY TRANSCRIPT: "Preliminary Transcript" indicates that the
Transcript has been published in near real-time by an experienced
professional transcriber. While the Preliminary Transcript is highly
accurate, it has not been edited to ensure the entire transcription
represents a verbatim report of the call.

EDITED TRANSCRIPT: "Edited Transcript" indicates that a team of professional
editors have listened to the event a second time to confirm that the
content of the call has been transcribed accurately and in full.

----

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.